Comparison
2p21 Microdeletion Syndrome Without Cystinuria C4749458 vs 15q11q13 Microduplication Syndrome C2675336
Clinical comparison between 2p21 Microdeletion Syndrome Without Cystinuria and 15q11q13 Microduplication Syndrome for differential diagnosis and treatment planning.
2p21 Microdeletion Syndrome Without Cystinuria C4749458
A chromosomal deletion on chromosome 2 involving some genes shared with another condition but without the kidney component. Supportive care addresses each person's specific needs.
15q11q13 Microduplication Syndrome C2675336
A genetic disorder involving duplication of material from the chromosome 15 region linked to Prader-Willi and Angelman syndromes. Features may include developmental delays, learning difficulties, and sometimes autism spectrum traits. Supportive therapies help manage symptoms.
6 comparison axes
Onset
2p21 Microdeletion Syndrome Without Cystinuria C4749458
0-null
15q11q13 Microduplication Syndrome C2675336
0-3
Onset patterns differ
Severity
2p21 Microdeletion Syndrome Without Cystinuria C4749458
severe
15q11q13 Microduplication Syndrome C2675336
moderate
Different severity levels
Chronic
2p21 Microdeletion Syndrome Without Cystinuria C4749458
Chronic
15q11q13 Microduplication Syndrome C2675336
Chronic
Differing course
Communicable
2p21 Microdeletion Syndrome Without Cystinuria C4749458
No
15q11q13 Microduplication Syndrome C2675336
No
Different transmission
Body System
2p21 Microdeletion Syndrome Without Cystinuria C4749458
congenital
15q11q13 Microduplication Syndrome C2675336
congenital
Same/different system
Category
2p21 Microdeletion Syndrome Without Cystinuria C4749458
rare-disease
15q11q13 Microduplication Syndrome C2675336
genetic
Different category
Bottom line
2p21-microdeletion-syndrome-without-cystinuria-C4749458 and 15q11q13-microduplication-syndrome-C2675336 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 2p21 Microdeletion Syndrome Without Cystinuria C4749458 | 15q11q13 Microduplication Syndrome C2675336 | Discriminating power |
|---|---|---|---|
| Chromosomal finding | Deletion involving 2p21, described without the cystinuria component. | Extra material from the 15q11q13 region. | High |
| Development and learning | A specific developmental profile is not established in the supplied data. | Developmental delay, learning difficulty, and sometimes autism-spectrum traits are described. | Moderate |
| Kidney involvement | The named condition is specified as without cystinuria; other kidney findings are not established. | Kidney disease is not described as a defining feature. | Moderate |
When to favor each condition
Choose 2p21 Microdeletion Syndrome Without Cystinuria C4749458 when
Testing confirms a 2p21 deletion and cystinuria is not present.
The diagnosis depends on the chromosomal finding and absence of that kidney component.
High
Counseling concerns a rare congenital deletion rather than 15q duplication.
The supplied axes assign different etiology and a severe category.
Moderate
Support needs must be planned without assuming a known symptom list.
Source data are sparse, so care should be individualized.
Moderate
Choose 15q11q13 Microduplication Syndrome C2675336 when
Testing confirms duplication of 15q11q13 material.
The syndrome is defined by that chromosomal region.
High
Developmental delay, learning difficulty, or autism-spectrum traits prompt evaluation.
These features are described, although they are not specific alone.
Moderate
Early childhood onset is documented.
The supplied onset axis is 0–3 years, unlike the unspecified left onset.
Low
How key tests differ
| Test | 2p21 Microdeletion Syndrome Without Cystinuria C4749458 | 15q11q13 Microduplication Syndrome C2675336 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or equivalent genetic test | Deletion at 2p21; exact breakpoints are not supplied. | Duplication involving 15q11q13. | The genomic result is the main discriminator and requires laboratory confirmation. |
| Urine cystine or renal assessment | Cystinuria is absent by definition; no cutoff is supplied. | No characteristic cystinuria result is described. | A normal or abnormal result does not by itself diagnose either condition. |
| Developmental and behavioral assessment | Expected profile is not established. | May show delay, learning difficulty, or autism-spectrum traits. | Findings guide support but do not replace genetic confirmation. |
Prognosis comparison
2p21 Microdeletion Syndrome Without Cystinuria C4749458
- Outcome
- Long-term outcome is not established; the supplied severity category is severe.
- Factors
- Confirmed deletion, absent cystinuria, and each person's associated needs.
15q11q13 Microduplication Syndrome C2675336
- Outcome
- Outcome varies; developmental and learning needs may be ongoing, with moderate supplied severity.
- Factors
- Duplication confirmation, developmental profile, and access to supportive therapies.
Time frame: Both are described as chronic; a precise time course is not established.
Genetic result, individual findings, comorbidities, and supportive care influence course.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurodevelopmental needs | Possible needs are not specifically established. Learning and developmental support needs are described. Severity and complications vary; clinician assessment is required. |
| Kidney-related complication | Cystinuria is specifically absent; other renal complications are not established. No defining kidney complication is supplied. Do not infer kidney disease from either diagnosis alone. |
| Associated medical complications | Not established from the supplied description. Beyond developmental features, complications are not established here. Surveillance should follow the individual's confirmed findings. |
Patient education highlights
- HighGenetic confirmation
The chromosomal test result distinguishes these conditions; symptoms alone are not definitive.
- HighIndividualized support
Supportive care addresses each person's developmental, learning, and medical needs.
- MediumLimits of current information
Prevalence, exact laboratory cutoffs, mortality, and treatment doses are not established here.